Biogen (NASDAQ: BIIB) recently won U.S. Food and Drug Administration (FDA) approval for its Alzheimer's disease drug Aduhelm. This decision was quite controversial, however, especially considering that the FDA's own advisory committee recommended against approval. In this Motley Fool Live video recorded on June 9, Motley Fool contributors Keith Speights and Brian Orelli discuss why the FDA overrode the advisory committee recommendation.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting